Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VCEL

Vericel Corp

Mar 18 • 02:01PM ET

47.12

Dollar change -0.48
Percentage change -1.01	%

Healthcare • Biotechnology • USA • NASD

Peers: MDXG ATRC OFIX PODD RVNC ICUI HAE APYX CUTR ENZ

| Held by: IJR VTI IWM VXF IJT XBI SPSM IWO IBB SLYG

Scroll to Statements

Index	RUT	P/E	255.25	EPS (ttm)	0.18	Insider Own	1.05%	Shs Outstand	49.63M	Perf Week	-1.44%
Market Cap	2.35B	Forward P/E	63.50	EPS next Y	0.74	Insider Trans	-30.40%	Shs Float	49.44M	Perf Month	-17.46%
Income	10.36M	PEG	2.87	EPS next Q	-0.13	Inst Own	105.19%	Short Float	7.88%	Perf Quarter	-17.35%
Sales	237.22M	P/S	9.93	EPS this Y	64.08%	Inst Trans	3.48%	Short Ratio	9.52	Perf Half Y	2.73%
Book/sh	5.88	P/B	8.01	EPS next Y	126.13%	ROA	2.64%	Short Interest	3.89M	Perf Year	6.58%
Cash/sh	2.54	P/C	18.58	EPS next 5Y	88.87%	ROE	4.00%	52W Range	39.12 - 63.00	Perf YTD	-14.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	2.71%	52W High	-25.21%	Beta	1.60
Dividend TTM	-	Quick Ratio	3.89	Sales past 5Y	15.33%	Gross Margin	72.55%	52W Low	20.45%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	4.23	EPS Y/Y TTM	400.58%	Oper. Margin	1.90%	RSI (14)	37.01	Volatility	4.84% 5.08%
Employees	357	Debt/Eq	0.34	Sales Y/Y TTM	20.10%	Profit Margin	4.37%	Recom	1.00	Target Price	65.38
Option/Short	Yes / Yes	LT Debt/Eq	0.31	EPS Q/Q	47.51%	Payout	0.00%	Rel Volume	0.81	Prev Close	47.60
Sales Surprise	-1.48%	EPS Surprise	18.90%	Sales Q/Q	15.97%	Earnings	Feb 27 BMO	Avg Volume	409.02K	Price	47.12
SMA20	-5.87%	SMA50	-14.51%	SMA200	-6.15%	Trades		Volume	235,372	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6
Mar-13-17	Reiterated	Needham	Buy	$9 → $6

Show Previous Ratings

Mar-04-25 08:30AM	Vericel to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 02:11AM	Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory (GuruFocus.com)
01:51AM	Q4 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:05AM	Vericel Corporation (VCEL) Tops Q4 Earnings Estimates (Zacks) -6.11%
07:54AM	Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
07:28AM	Loading…
Feb-26-25 07:28AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q4 2024 Result (GuruFocus.com)
Feb-13-25 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-14-25 04:05PM	Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets (GlobeNewswire)
Jan-08-25 08:30AM	Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 (GlobeNewswire)
Dec-19-24 07:36AM	Vericel price target raised to $67 from $61 at Truist (TipRanks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily) +5.15%
Nov-08-24 04:03AM	Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ... (GuruFocus.com) +7.94%
Nov-07-24 09:10AM	Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:15AM	Vericel Corp (VCEL) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +7.35%
08:30AM	Loading…
Oct-24-24 08:30AM	Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-22-24 09:31AM	Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half (Insider Monkey)
Oct-18-24 03:04PM	State Street Corp's Strategic Reduction in Vericel Corp Holdings (GuruFocus.com)
Oct-09-24 03:44PM	Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
07:01PM	Loading…
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance (GlobeNewswire)
Feb-27-24 08:30AM	Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 (GlobeNewswire)
Feb-22-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice (Zacks)
Feb-18-24 03:00AM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Feb-15-24 10:00AM	Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:50AM	Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 (GlobeNewswire)
Jan-30-24 11:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
08:50AM	Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why (Zacks)
Jan-25-24 09:49AM	Tesla, Boeing downgraded: Wall Street's top analyst calls (The Fly)
Jan-24-24 07:01PM	Director ZERBE ROBERT L MD Sells 8,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jan-19-24 08:28PM	Vericel Corp President and CEO Dominick Colangelo Sells 33,452 Shares (GuruFocus.com) +5.95%
Jan-09-24 08:47AM	Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last? (Zacks) +7.24%
07:55AM	Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:30AM	Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 (GlobeNewswire)
Dec-17-23 03:01AM	Insider Sell: Director Paul Wotton Offloads 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-09-23 03:05AM	Insider Sell: President and CEO Dominick Colangelo Sells 24,397 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Dec-02-23 05:04AM	Insider Sell: COO Michael Halpin Sells 17,447 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-23-23 07:04AM	Insider Sell: Chief Medical Officer Jonathan Hopper Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Nov-16-23 05:35PM	3 Biotech Stocks That Could Boom or Bust by 2025 (InvestorPlace)
Nov-10-23 09:52PM	3 Strong Buy Stocks Set to Take Off in the Coming Months (InvestorPlace)
Nov-09-23 03:56PM	Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.05%
Nov-08-23 03:30PM	Vericel Corp (VCEL) Reports Strong Q3 2023 Results and Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Nov-07-23 08:30AM	Vericel to Present at the Stephens Annual Investment Conference (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-25-23 08:30AM	Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-24-23 01:22AM	Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen (Zacks) +5.70%
Oct-23-23 05:59PM	Top Medical Stocks to Buy Amid Recent Market Volatility (Zacks)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +6.34%
Sep-28-23 08:30AM	Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid (GlobeNewswire)
Sep-20-23 04:30PM	Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire) +5.14%
Sep-06-23 08:30AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 01:48AM	Vericel Corp. (VCEL) Rose on Positive Trend in the Industry (Insider Monkey)
Aug-02-23 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
Jul-23-23 11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jul-20-23 08:30AM	Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-10-23 09:30AM	Vericel (NASDAQ:VCEL) shareholders are still up 286% over 5 years despite pulling back 4.5% in the past week (Simply Wall St.)
Jun-21-23 08:00PM	VCEL: What does Argus have to say about VCEL? (Argus Research)
May-10-23 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance (GlobeNewswire)
May-02-23 09:00AM	Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (PR Newswire)
Apr-26-23 08:00PM	VCEL: Lowering target price to $32.00 (Argus Research)
08:30AM	Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-24-23 02:06AM	Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains? (Zacks)
Apr-17-23 03:03PM	Little Excitement Around Vericel Corporation's (NASDAQ:VCEL) Revenues (Simply Wall St.)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colangelo Dominick	President and CEO	Mar 13 '25	Option Exercise	1.95	26,592	51,854	286,589	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 12 '25	Option Exercise	1.95	26,591	51,852	286,588	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 12 '25	Sale	46.31	26,591	1,231,429	259,997	Mar 14 04:07 PM
Colangelo Dominick	President and CEO	Mar 13 '25	Sale	45.78	26,592	1,217,382	259,997	Mar 14 04:07 PM
Colangelo Dominick	Officer	Mar 13 '25	Proposed Sale	45.78	26,592	1,217,281		Mar 13 04:19 PM
Colangelo Dominick	Officer	Mar 12 '25	Proposed Sale	46.31	26,591	1,231,364		Mar 12 04:14 PM
Halpin Michael	Chief Operating Officer	Mar 03 '25	Option Exercise	16.66	10,000	166,600	25,359	Mar 05 04:05 PM
Halpin Michael	Chief Operating Officer	Mar 03 '25	Sale	49.52	10,000	495,200	15,539	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Option Exercise	3.74	9,000	33,660	37,650	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Sale	49.53	9,000	445,770	28,650	Mar 05 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Mar 03 '25	Sale	49.53	9,000	445,770	13,967	Mar 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Mar 03 '25	Option Exercise	18.00	10,000	180,000	76,101	Mar 05 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Mar 03 '25	Sale	49.53	10,000	495,300	66,101	Mar 05 04:05 PM
Hagen Heidi	Director	Mar 03 '25	Proposed Sale	51.20	9,000	460,800		Mar 03 11:29 AM
Hopper Jonathan Mark	Officer	Mar 03 '25	Proposed Sale	51.20	10,000	512,000		Mar 03 11:04 AM
Mara Joseph Anthony Jr	Officer	Mar 03 '25	Proposed Sale	51.20	9,000	460,800		Mar 03 11:00 AM
Halpin Michael	Officer	Mar 03 '25	Proposed Sale	51.20	10,000	512,000		Mar 03 10:47 AM
Hopper Jonathan Mark	Chief Medical Officer	Feb 24 '25	Option Exercise	0.00	1,500	0	66,737	Feb 26 04:05 PM
Colangelo Dominick	President and CEO	Feb 24 '25	Option Exercise	0.00	18,250	0	268,456	Feb 26 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 24 '25	Option Exercise	0.00	5,250	0	18,025	Feb 26 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 24 '25	Option Exercise	0.00	4,625	0	24,325	Feb 26 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 24 '25	Option Exercise	0.00	3,000	0	3,756	Feb 26 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 25 '25	Sale	52.07	1,669	86,905	756	Feb 26 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 24 '25	Option Exercise	0.00	1,875	0	3,081	Feb 26 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 25 '25	Sale	52.07	1,137	59,204	1,206	Feb 26 04:05 PM
Flynn Sean C.	Officer	Feb 25 '25	Proposed Sale	52.07	1,669	86,905		Feb 25 12:20 PM
SIEGAL JONATHAN	Officer	Feb 25 '25	Proposed Sale	52.07	1,137	59,204		Feb 25 12:00 PM
Flynn Sean C.	Chief Legal Officer	Feb 20 '25	Sale	57.32	3,835	219,822	756	Feb 24 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 18 '25	Option Exercise	0.00	2,325	0	63,825	Feb 20 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Feb 19 '25	Option Exercise	0.00	1,750	0	64,590	Feb 20 04:05 PM
Colangelo Dominick	President and CEO	Feb 18 '25	Option Exercise	0.00	11,700	0	250,887	Feb 20 04:05 PM
Colangelo Dominick	President and CEO	Feb 19 '25	Option Exercise	0.00	8,938	0	254,402	Feb 20 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 18 '25	Option Exercise	0.00	5,325	0	4,650	Feb 20 04:05 PM
Flynn Sean C.	Chief Legal Officer	Feb 19 '25	Option Exercise	0.00	1,750	0	5,368	Feb 20 04:05 PM
Mara Joseph Anthony Jr	Chief Financial Officer	Feb 18 '25	Option Exercise	0.00	7,379	0	20,509	Feb 20 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 18 '25	Option Exercise	0.00	2,920	0	3,706	Feb 20 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 18 '25	Option Exercise	0.00	9,075	0	13,106	Feb 20 04:05 PM
Halpin Michael	Chief Operating Officer	Feb 19 '25	Option Exercise	0.00	2,813	0	14,107	Feb 20 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 19 '25	Sale	56.72	1,710	96,991	1,206	Feb 20 04:05 PM
Flynn Sean C.	Officer	Feb 20 '25	Proposed Sale	57.32	3,835	219,822		Feb 20 11:14 AM
SIEGAL JONATHAN	Officer	Feb 19 '25	Proposed Sale	56.72	1,710	96,991		Feb 19 09:54 AM
MCLAUGHLIN KEVIN F	Director	Feb 12 '25	Option Exercise	3.60	7,000	25,200	17,900	Feb 14 04:05 PM
MCLAUGHLIN KEVIN F	Director	Feb 12 '25	Sale	55.46	7,000	388,250	11,900	Feb 14 04:05 PM
MCLAUGHLIN KEVIN F	Director	Feb 12 '25	Proposed Sale	55.46	7,000	388,236		Feb 12 04:08 PM
Rubino Alan L	Director	Feb 07 '25	Option Exercise	3.74	19,000	71,060	42,794	Feb 11 04:05 PM
ZERBE ROBERT L MD	Director	Feb 05 '25	Option Exercise	13.05	2,500	32,625	29,095	Feb 07 04:18 PM
ZERBE ROBERT L MD	Director	Feb 05 '25	Sale	62.50	2,500	156,250	26,595	Feb 07 04:18 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 05 '25	Option Exercise	48.80	1,092	53,290	2,298	Feb 07 04:12 PM
SIEGAL JONATHAN	Principal Accounting Officer	Feb 05 '25	Sale	61.99	1,092	67,693	1,206	Feb 07 04:12 PM
ZERBE ROBERT L MD	Director	Feb 05 '25	Proposed Sale	62.50	2,500	156,250		Feb 05 10:15 AM
SIEGAL JONATHAN	Officer	Feb 05 '25	Proposed Sale	61.99	1,092	67,693		Feb 05 10:12 AM
SIEGAL JONATHAN	Principal Accounting Officer	Jan 28 '25	Option Exercise	48.80	3,908	190,710	5,114	Jan 30 04:05 PM
SIEGAL JONATHAN	Principal Accounting Officer	Jan 28 '25	Sale	61.99	3,908	242,257	1,206	Jan 30 04:05 PM
SIEGAL JONATHAN	Officer	Jan 28 '25	Proposed Sale	61.99	3,908	242,257		Jan 28 04:07 PM
Wotton Paul K	Director	Dec 04 '24	Sale	58.72	2,600	152,672	27,402	Dec 05 04:05 PM
Wotton Paul K	Director	Dec 04 '24	Proposed Sale	83.76	2,600	217,782		Dec 04 10:37 AM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '24	Option Exercise	16.66	10,000	166,600	68,371	Dec 03 04:05 PM
Hopper Jonathan Mark	Chief Medical Officer	Dec 02 '24	Sale	58.72	10,000	587,200	58,371	Dec 03 04:05 PM
Hopper Jonathan Mark	Officer	Dec 02 '24	Proposed Sale	57.95	10,000	579,500		Dec 02 03:14 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 25 04:05 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Sale	60.00	2,500	150,000	26,595	Nov 25 04:05 PM
ZERBE ROBERT L MD	Director	Nov 22 '24	Proposed Sale	60.00	2,500	150,000		Nov 22 04:26 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Option Exercise	3.74	7,000	26,180	18,900	Nov 15 04:05 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Sale	55.54	7,000	388,780	11,900	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 13 '24	Option Exercise	3.02	17,500	52,850	238,437	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 14 '24	Option Exercise	3.02	17,500	52,850	238,437	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 13 '24	Sale	55.57	17,500	972,475	220,937	Nov 15 04:05 PM
Colangelo Dominick	President and CEO	Nov 14 '24	Sale	53.93	17,500	943,775	220,937	Nov 15 04:05 PM
Colangelo Dominick	Officer	Nov 14 '24	Proposed Sale	53.93	17,500	943,758		Nov 14 04:11 PM
Colangelo Dominick	Officer	Nov 13 '24	Proposed Sale	55.57	17,500	972,477		Nov 13 04:29 PM
MCLAUGHLIN KEVIN F	Director	Nov 13 '24	Proposed Sale	55.54	7,000	388,802		Nov 13 04:09 PM
ZERBE ROBERT L MD	Director	Nov 11 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Option Exercise	13.05	2,500	32,625	29,095	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Sale	57.50	2,500	143,750	26,595	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 11 '24	Sale	55.00	2,500	137,500	26,595	Nov 13 04:05 PM
ZERBE ROBERT L MD	Director	Nov 12 '24	Proposed Sale	57.50	2,500	143,750		Nov 12 12:42 PM
Hagen Heidi	Director	Oct 17 '24	Option Exercise	3.74	10,000	37,400	28,650	Oct 21 04:05 PM
Colangelo Dominick	President and CEO	Oct 16 '24	Option Exercise	3.02	17,500	52,850	238,437	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 17 '24	Option Exercise	3.02	17,500	52,850	238,437	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 16 '24	Sale	41.38	17,500	724,150	220,937	Oct 18 04:05 PM
Colangelo Dominick	President and CEO	Oct 17 '24	Sale	40.34	17,500	705,950	220,937	Oct 18 04:05 PM
GILMAN STEVEN C	Director	Oct 16 '24	Option Exercise	13.05	5,833	76,121	16,833	Oct 18 04:05 PM
GILMAN STEVEN C	Director	Oct 16 '24	Sale	41.36	5,833	241,253	11,000	Oct 18 04:05 PM
Colangelo Dominick	Officer	Oct 17 '24	Proposed Sale	40.34	17,500	705,983		Oct 17 04:27 PM
Colangelo Dominick	Officer	Oct 16 '24	Proposed Sale	41.38	17,500	724,173		Oct 16 04:43 PM
GILMAN STEVEN C	Director	Oct 16 '24	Proposed Sale	41.36	5,833	241,270		Oct 16 04:31 PM
GILMAN STEVEN C	Director	Oct 02 '24	Option Exercise	13.05	5,833	76,121	16,833	Oct 04 04:06 PM
GILMAN STEVEN C	Director	Oct 02 '24	Sale	40.35	5,833	235,362	11,000	Oct 04 04:06 PM
GILMAN STEVEN C	Director	Oct 02 '24	Proposed Sale	40.35	5,833	235,373		Oct 02 04:54 PM
SIEGAL JONATHAN	Principal Accounting Officer	Sep 30 '24	Option Exercise	0.00	937	0	2,061	Oct 02 04:06 PM
SIEGAL JONATHAN	Principal Accounting Officer	Oct 01 '24	Sale	41.90	568	23,799	1,124	Oct 02 04:06 PM
SIEGAL JONATHAN	Officer	Oct 01 '24	Proposed Sale	41.90	568	23,799		Oct 01 01:16 PM
GILMAN STEVEN C	Director	Sep 18 '24	Option Exercise	13.05	5,834	76,134	16,834	Sep 20 04:05 PM
GILMAN STEVEN C	Director	Sep 18 '24	Sale	45.54	5,834	265,680	11,000	Sep 20 04:05 PM
GILMAN STEVEN C	Director	Sep 18 '24	Proposed Sale	45.54	5,834	265,674		Sep 18 04:10 PM
Colangelo Dominick	President and CEO	Sep 11 '24	Option Exercise	3.02	17,500	52,850	238,437	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 12 '24	Option Exercise	3.02	17,500	52,850	238,437	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 12 '24	Sale	43.90	17,500	768,250	220,937	Sep 13 04:05 PM
Colangelo Dominick	President and CEO	Sep 11 '24	Sale	43.37	17,500	758,975	220,937	Sep 13 04:05 PM
Colangelo Dominick	Officer	Sep 12 '24	Proposed Sale	43.90	17,500	768,329		Sep 12 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCEL

Vericel Corp

Upgrade your FINVIZ experience